Abstract

Purpose: To explore the effect of continuous quality improvement (CQI) of radiation safety management for patients administerediodine-131 after thyroid cancer surgery. Methods: A total of 103 patients with differentiated thyroid carcinoma were randomly divided into control and experimental groups containing 51 and 52 patients, respectively. In the control group, the drug was administered according to the operating procedure for iodine-131 treatment of thyroid carcinoma. In the experimental group, CQI was adopted to manage the radiation safety of care in addition to the conventional iodine-131 thyroid cancer treatment procedures. We also improved radiation safety protection measures prior to drug administration, developed a flow chart of drug administration for patients, established a patient preview of the drug administration process, and enhanced health education and psychological intervention for the patient. Results: The environmental radiation around the drug delivery window was reduced (P< 0.05), total duration of exposure to the radiation was shortened (P< 0.05), drug drop rate was decreased to 0%, and patient satisfaction was improved in the experimental group compared to the control group. Conclusions: Application of CQI for management of radiation safety when treating thyroid cancer withiodine-131 can improve patient treatment, quality of care, and satisfaction and reduce radiation pollution in the surrounding environment and radiation injury to staff.

Highlights

  • The iodine-131 is widely used in the treatment of differentiated thyroid carcinoma [1,2,3]

  • The objective of our study is to assess the influence of Continuous quality improvement of radiation safety management for treatment of differentiated thyroid carcinoma with iodine-131

  • 103 patients with differentiated thyroid cancer that was treated with iodine-131 in our hospital's nucleus ward were enrolled in this study, and divided randomly into control and experimental groups

Read more

Summary

Introduction

The iodine-131 is widely used in the treatment of differentiated thyroid carcinoma [1,2,3]. According to the Law of the People's Republic of China on the Prevention and Control of Radioactive Pollution and the Regulations on the Safety and Protection of Radioisotopes and Radiation Devices, when radiopharmaceuticals are employed, radiation protection and safety issues should be considered in addition to the chemical and biological properties of the drug [2]. Supervision of radioactive source and device safety in hospitals should be strengthened, radiation safety accidents should be reduced, the ability to respond to radiation accidents should be improved, and the consequences of accidents should be controlled and mitigated. According to the routine regulations during the treatment Urinary iodine concentration (UIC) from spot urine reflects recent die tartare intake (hours to days) and can have high daily variability [4, 5].

Objectives
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.